Well-con­nect­ed, Gilead-backed biotech gets an­oth­er stack of cash to pur­sue CAR-Ts for au­toim­mune dis­ease

Al­most ex­act­ly two years af­ter its de­but at the 2020 JP Mor­gan con­fab — and on the heels of a new part­ner­ship with the gene edit­ing ex­perts at In­tel­lia — a Gilead-backed, au­toim­mune dis­ease-fo­cused start­up has re­turned to the well with a clear­er out­line of just what it plans to do with its CAR-T plat­form.

Kyver­na brought in $85 mil­lion in its over­sub­scribed Se­ries B, the com­pa­ny an­nounced Wednes­day. North­pond Ven­tures led the round, and West­lake Vil­lage BioPart­ners, Vi­da Ven­tures, Gilead and In­tel­lia all con­tributed as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER